DUBLIN, Feb. 28, 2018 /PRNewswire/ — Allergan plc, (NYSE: AGN) a leading global pharmaceutical company, today announced that it was notified by the U.S. Food and Drug Administration (FDA) that the review of the New Drug Application (NDA) for…Original Article
Allergan Announces FDA Has Extended The Ulipristal Acetate NDA Review Period To August 2018
